The following is a quick summary of interesting reports in the literature for June 2023.
COVID-19
CNS infection
Alzheimer’s disease
Biomarkers
Headache
Multiple sclerosis
Neurodegenerative disorders
Neuromyelitis optica
Stroke Read More
Neurology
Novel approach to MS therapeutics: anti-CD40L
June 21, 2023CMSC 2023
An emerging therapeutic target of interest is CD40 and its ligand (CD40L), which initially drew attention for their role in activating B cells and macrophages in response to infection (reviewed in Ots et al. Int J Mol Sci 2022;23:4115). Subsequent investigations implicated abnormal CD40 expression in a number of neurological disorders, including multiple sclerosis. Read More
Re-evaluating the balance of efficacy and safety with disease-modifying therapies
June 8, 2023Includes data on early use of high-efficacy DMTs, risks of undertreatment of MS, safety issues and de-risking anti-CD20 therapy during long-term use.
16 slides
Selected highlights from CMSC 2023
June 6, 2023The Consortium of MS Clinics (CMSC) annual meeting concluded on June 3, 2023. The following are some selected highlights from the symposium. Read More
NfL – a guide to use in MS practice
May 31, 2023Neurofilament-light chain (NfL) has emerged as one of the more promising biomarkers in multiple sclerosis. Neurofilaments are proteins expressed by axons and released into the cerebrospinal fluid, a process that is accelerated with neuroaxonal damage. It has not been determined if elevated concentrations of NfL are due to increased expression and/or release of NfL, impaired clearance of NfL by microglia, or other factors. While the current understanding of NfL is incomplete, an elevated concentration in CSF, plasma or serum, although not specific to MS, is a potentially useful biomarker of axonal damage. Read More